An experimental drug has shown promise in preventing emphysema in mice exposed to cigarette smoke, giving researchers new hope that they’ll soon find a way to combat one of the most stubborn, untreatable, and common killers of humans. Even though the study focuses on emphysema in mice, the researchers suggest the drug could work in people by delaying or preventing chronic obstructive pulmonary disease, which encompasses emphysema and chronic bronchitis and is the fourth most common cause of death in the United States [Science News].
The drug, called CDDO-imidazole, or CDDO-Im, works by activating a gene called Nrf2, explains study coauthor Shyam Biswal. In prior research, Biswal and colleagues found that Nrf2 works as a “master gene,” turning on genes involved in protecting the lungs from pollution and cigarette smoke. “The Nrf2 pathway is the major antioxidant and detoxifying response in the lungs. Therapies targeting this pathway need to be developed and tested in patients,” said Biswal [Reuters].
In the study, which will be published in the Proceedings of the National Academy of Sciences, researchers had mice inhale cigarette smoke for five hours a day, and fed half the mice food treated with the drug. Those mice on the drug regimen produced more antioxidants that kept their lung cells from dying and decreased inflammation in the lung tissue; those mice also showed fewer symptoms of heart disease. Antioxidants work by neutralizing the damaging molecules called free radicals that are introduced by the inhalation of cigarette smoke. Prodding the body to produce more of its own homemade antioxidants is a better approach than trying to consume them, such as by taking vitamins C and E, says Biswal [Science News].
The research will give pharmaceutical companies a new avenue to pursue as they search for emphysema treatments, said lung disease expert James Kiley. “Is it going to bring a new therapy tomorrow?” said Kiley, who wasn’t involved in the study. “Absolutely not. We don’t have any therapies that will cure the disease or halt the progression once it’s started, so it’s a step toward that” [Bloomberg].
Image: flickr / SuperFantastic
December 23rd, 2008 at 11:20 am
Another company is showing success against COPD with rta402 (rta402.com), which is in phase 2 studies now. With luck, Obama will clean up the lethargic FDA and get important drugs approved a lot faster than in the past.
December 23rd, 2008 at 12:12 pm
1) Humans cannot produce Vitamins C or E.
2) I you want phenolic antioxidants by the hogshead, eat cocoa.
3) Phenolic antioxidants like BHA, BHT, Trolox, nordihydroguaiaretic acid… are hepatotoxic. If you buy pharma with a low serial number you might get Microcrap Vista in a pill.
4) 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole (CDDO-Im) exhibits a broad spectrum of cellular proliferation, differentiation, and apoptotsis effects, PNAS 102 4584-4589 (2005)
5) http://www.amsar.com/img/oleanolic.jpg
http:// http://www.freepatentsonline.com/6974801.html
6) Somebody should cyclopropanate the carbonyl-conjugated olefin into both stereoisomers for SAR pharma fun.
December 9th, 2009 at 2:44 pm
No one is saying humans produce Vitamins C or E. The article says taking vitamins that stimulate natural production of antioxidants is more effective than directly consuming antioxidants.
retard